AJMC November 25, 2025
Key Takeaways
- DTC models streamline drug access by bypassing intermediaries, offering pricing transparency and control over distribution, but may increase out-of-pocket costs for patients.
- Major pharmaceutical companies like Eli Lilly, Pfizer, and Novo Nordisk have launched DTC platforms, providing telehealth services, home delivery, and affordability programs.
- TrumpRx, launching in 2026, aims to offer discounted drugs directly from manufacturers, but its impact on simplifying the system and reducing costs remains uncertain.
- Experts highlight the importance of patient education to ensure informed decisions, as DTC models may complicate medication management and financial planning.
The expansion of direct-to-consumer (DTC) pharmaceutical manufacturer models and the upcoming TrumpRx launch offer lower costs but create new complexities for patients.
As pharmaceutical companies rapidly expand...
Today's Sponsors
Today's Sponsor